The Federal Court of Australia has found that an advertising
campaign by the makers of Nurofen (claiming its product was
superior to a competitor's) was misleading and deceptive. This
is the second time in recent years that the maker has been under
scrutiny for such conduct, with the Court due to make final orders
in mid-February 2018. This case, along with the earlier
proceedings, highlight the care that should be taken when you and
your business consider making public claims about your products
and/or services—particularly when comparing products to those
of a competitor.
Competitor's campaign shut down
In August 2015, Reckitt Benckiser (Reckitt) commenced a
comparative advertising campaign in which Nurofen was compared with
Panadol. Reckitt claimed Nurofen and ibuprofen is better, faster
acting and more effective than Panadol and paracetamol for
delivering pain relief for common headaches. GlaxoSmithKline (GSK),
the makers of Panadol, alleged that the